Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Deciphera Pharmaceuticals to Present Clinical Data on Tumor Targeted Advanced Kinase Inhibitors at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Deciphera Pharmaceuticals,LLC
Posted on: 31 Oct 16

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing tumor-targeted and immuno-targeted advanced kinase inhibitors, announced today that two abstracts featuring the Company’s clinical-stage tumor-targeted therapies have been selected for a late-breaking oral presentation and a poster discussion at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 to December 2, 2016 in Munich, Germany.

DCC-2618 is a pan-KIT and PDGFRα kinase inhibitor in clinical development for the treatment of genetically-defined cancers, including gastrointestinal stromal tumors (GIST) and other KIT-driven cancers such as systemic mastocytosis. Altiratinib is a spectrum selective inhibitor of MET, TRK, TIE2 & VEGFR2 kinases in clinical development for the treatment of solid tumors. DCC-2618 and altiratinib are both currently in Phase 1 first-in-human studies.

“Genetically-defined cancers with specific kinase mutations, such as gastrointestinal stromal tumors and systemic mastocytosis, are ideal targets for our advanced kinase inhibitors and we look forward to sharing clinical data on DCC-2618 and altiratinib at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,” stated Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals.

Late-breaking Oral Presentation:



DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept

in a first-in-human study

Author: Janku, F., MD Anderson Cancer Center
Abstract: 7LBA
Session: Plenary Session 6: Proffered Paper Session
Date/Time: Thursday, December 1, 2016, 4:10 p.m. (CET)

Poster Presentation:




The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits

resistant NTRK kinase domain mutants

Author: Drilon, A.
Abstract/Board: 422/P101
Session: Poster Session: Molecular targeted agents II
Date/Time: Thursday, December 1, 2016, 10:15 a.m. - 5:00 p.m. (CET)

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing innovative kinase inhibitor therapies that address key drug resistance mechanisms. Deciphera’s unique approach leverages its deep understanding of kinase biology to develop a robust pipeline of tumor-targeted and immuno-targeted drug candidates that can improve the rate and durability of response to treatment. Deciphera’s innovative switch control platform enables the creation of tumor-targeted agents designed to control therapeutic resistance causing mutations and immuno-targeted agents designed to control activation of immuno-kinases that suppress critical immune system regulators, such as macrophages. This two-pronged approach to kinase inhibition represents an advance over other methods of inhibiting kinases for the treatment of cancer.

View source version on

Business Wire

Last updated on: 31/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.